– USA, NY – Aevitas Therapeutics, Inc., a Fortress Biotech, Inc. (Nasdaq: FBIO) partner company focused on the development of novel gene therapy approaches for complement-mediated diseases, today announced the appointment of Dr. Markus Peters, Ph.D., as President and CEO.
Dr. Peters was most recently the COO of Gemini Therapeutics after serving as the Chief Commercial Officer of Agilis Biotherapeutics.
Dr. Peters will lead the Company as it advances its proprietary platform designed to deliver engineered, fully functional, shortened complement factor H via an adeno-associated virus.
“We are pleased to welcome Markus as CEO. His extensive experience with AAV-based gene therapies and complement-mediated diseases, strong global biopharma leadership background, and expertise in the development of novel therapeutics will benefit Aevitas as we advance our shortened CFH gene platform.” said Dr. Lindsay Rosenwald, Fortress’ Chairman and CEO and Aevitas’ Executive Chairman.
Aevitas also appointed Dr. Catherine Bowes Rickman, Ph.D., FARVO, a leading AMD researcher, to its Scientific Advisory Board to support the advancement of its innovative program for the treatment of dry AMD. She will join Scientific Founder, Dr. Wenchao Song, Ph.D. of the University of Pennsylvania, and Dr. Guangping Gao, Ph.D. of the University of Massachusetts Medical School. Over the last decade, Dr. Bowes Rickman has focused her research on the impact of the complement system on the pathobiology of AMD.
Dr. Lindsay Rosenwald added: “We also welcome Dr. Bowes Rickman to Aevitas’ SAB. Her expertise in AMD and research establishing the key role CFH plays in disease progression and susceptibility, will be invaluable. “With an experienced team and collaborations with leading academic institutions, Aevitas is well-positioned to advance with due urgency potential therapies for patients with genetic diseases of the complement system, providing value through the application of its proprietary AAV platform.”
About Dr. Markus Peters
Dr. Peters has a 25-year track record of developing and commercializing innovative, high-value orphan and specialty pharmaceuticals for patients with a significant unmet medical need. Most recently, he was COO at Gemini Therapeutics, a precision medicine company developing novel therapeutics to treat genetically defined age-related macular degeneration and related disorders. There, he had responsibility for financing, corporate and pipeline strategy, business development, human resources, and general administration. Before Gemini, Dr. Peters was Chief Commercial Officer at Agilis Biotherapeutics, a company developing gene therapies for patients with rare diseases of the central nervous system which was acquired in 2018 by PTC Therapeutics in a milestone-based deal valued at $1B. Before that, Dr. Peters held leading commercial roles at Synageva BioPharma up to its acquisition by Alexion Pharmaceuticals for $8.4B in 2015, and at Alexion where he launched the blockbuster Soliris for the atypical hemolytic uremic syndrome as head of global marketing. Earlier in his career, Dr. Peters served in pipeline planning and commercial roles with increasing responsibility at Merck, Wyeth/Pfizer, and Boehringer Ingelheim, spending several years working in Europe, Japan and China.
“I am excited to be joining Aevitas at this critical juncture for the company, as it advances towards clinical trials,” said Dr. Peters.
Dr. Peters received his Ph.D. in Biochemistry and M.Sc. in Chemistry (Dipl. Chem.) from Heinrich-Heine University Düsseldorf in Germany.
About Dr. Catherine Bowes Rickman
Dr. Bowes Rickman is a tenured Professor of Ophthalmology and Cell Biology at Duke University. She has a long-standing interest in age-related macular degeneration and has become a leader in the development and use of murine models to elucidate the mechanisms of pathology and progression for AMD. She has developed several mouse models that recapitulate many aspects of the human AMD phenotype where she examines the pathogenic contribution of genetic, inflammatory, and environmental factors to AMD onset and progression. She has spent the last decade focusing her research on studying the impact of the complement system on the pathobiology of AMD.
About Aevitas Therapeutics
Aevitas Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel adeno-associated virus-based gene therapies for complement-mediated diseases. Aevitas aims to develop these potentially lifelong cures in multiple disease areas, including age-related macular degeneration, atypical hemolytic uremic syndrome, and paroxysmal nocturnal hemoglobinuria. Aevitas was founded by Fortress Biotech, Inc. (Nasdaq: FBIO).
About Fortress Biotech
Fortress Biotech, Inc. is an innovative biopharmaceutical company that was ranked in Deloitte’s 2019 and 2020 Technology Fast 500, annual rankings of the fastest-growing North American companies in the technology, media, telecommunications, life sciences, and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing, and commercializing high-potential marketed and development-stage drugs and drug candidates. The company has five marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases, and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals Inc., St. Jude Children’s Research Hospital and Nationwide Children’s Hospital.
For more information: https://www.fortressbiotech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.